Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

The decrease of similarity between the displacement of the center of pressure (COP) and the gaze point inhibited the displacement of the COP. by Hikaru Nakahara (13955347)

Proportion of individuals’ general benefits scores that increased, decreased, or remained unchanged between time points. by Jessie B. Moore (12578140)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Sliding Dynamics of a Small Charged Ring Chain on the Diblock Polyelectrolyte in Poly[2]catenane in the Presence of Counterions by Zhiyong Yang (11266)

Subjects:

Sliding Dynamics of a Small Charged Ring Chain on the Diblock Polyelectrolyte in Poly[2]catenane in the Presence of Counterions by Zhiyong Yang (11266)

Subjects:

Sliding Dynamics of a Small Charged Ring Chain on the Diblock Polyelectrolyte in Poly[2]catenane in the Presence of Counterions by Zhiyong Yang (11266)

Subjects:

Decrease of autoantibody levels in highly inflammatory NSG mice. by Henrika Jodeleit (4722312)

DART-ID decreases missing datapoints across runs. by Albert Tian Chen (6900215)

“…Only peptides seen in >50% of experiments are included. (<b>b</b>) Decrease in missing data across all runs after applying DART-ID, for SCoPE-MS and the two bulk sets from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007082#pcbi.1007082.g004" target="_blank">Fig 4</a> at 1% FDR. …”

S10 Fig - by Mark J. Carroll (3605582)

Trust levels before and after the COVID-19 pandemic (n = 10,000). by Alain Abi-Rizk (8549358)

Lung tumor development decreases the proportions of CD103⁺XCR1⁺ DC1s. by Julyanne Brassard (4117441)

Effect of 10 ng of IL-1β and IL-1Ra in a preliminary recording of the LFPs in the OB. by Adriana Jiménez (3551204)

“…<p>A) A single dose of 10 ng of IL-1β decreased the amplitude of LFPs in the OB immediately after its microinjection, reaching a maximum effect at approximately 10 min and remaining constant for at least 45 min. …”

Homozygous deletion of <i>ERG251</i> leads to the decreased ergosterol accumulation in the absence of FLC and decreased production of toxic dienol in the presence of FLC. by Xin Zhou (54275)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Decrease in salivary TTV titer (log₁₀ titer/ml) in individuals positive for SARS-CoV-2 as a function of time from symptom onset. by Maria C. Mendes-Correa (11326465)